Biogen and Eisai shares jump on full lecanemab data

30 November 2022
neuroscience_cns_brain_large

With each step made towards market for lecanemab, the sorry saga of its failed predecessor Aduhelm (aducanumab) seems further away for Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523).

The latest update on lecanemab led the drug companies behind both Alzheimer’s disease candidates to gain ground during Wednesday’s stock market trading, with Eisai closing nearly 4% higher and Biogen up by 5% by lunchtime.

"This is only a start to stopping Alzheimer’s"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology